Biotechnology News and Research

RSS

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Generex Biotechnology Corporation, the leader in drug delivery for metabolic diseases through the inner lining of the mouth, today announced that it has expanded its plans for its United States Food and Drug Administration (FDA) Expanded Access Treatment IND Program for its flagship product, Generex Oral-lyn™, to include licensed and qualified Nurse Practitioners in the United States.

29 Mar 2010

Neogen's third-quarter fiscal 2010 revenues up 21%

Neogen Corporation announced today that its net income for the third quarter of FY 2010, which ended Feb. 28, increased 38% from the previous year to $3,881,000. Adjusted for a 3-for-2 stock split effective Dec. 15, net income in the quarter rose to $0.17 per share, compared to the prior year's $0.12.

29 Mar 2010

Chakra Biotech completes MYR18.2m Series B investment round

Chakra Biotech Sdn Bhd, a Malaysian based Contract Research Organization, has completed a MYR18.2m Series B funding round. This brings total funding for the company to MYR20.0m. Malaysian Life Sciences Capital Fund Ltd. (MLSCF) and the Malaysian Technology Development Corporation Sdn Bhd (MTDC) participated in the round.

29 Mar 2010

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Novavax, Inc. a clinical-stage vaccine company, released the final results from a Phase II clinical trial evaluating Novavax's trivalent seasonal influenza Virus-like particle (VLP) vaccine candidate in healthy adults. The study enrolled healthy volunteers 18 to 49 years in age who were immunized with a single injection of Novavax's trivalent seasonal influenza VLP vaccine matched to the influenza strains recommended for the 2008-2009 influenza vaccine.

29 Mar 2010

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Ligand Pharmaceuticals Incorporated today announced that data from a Phase I study with its selective androgen receptor modulator (SARM) LGD-4033 was featured today in a poster presentation at the 14th International Congress of Endocrinology in Kyoto, Japan. This Phase I clinical trial was the first study in humans of LGD-4033, and evaluated the safety, tolerability and pharmacokinetic profiles of the molecule in a single escalating dose, double blind, placebo-controlled study in 48 healthy volunteers.

29 Mar 2010

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Celerion, a privately owned contract research organization (CRO), has completed the acquisition of the development and regulatory services consultancy and early stage development operations of MDS Pharma Services. The acquired assets include five clinical research facilities and two bioanalytical laboratories located in Lincoln, Nebraska; Neptune, New Jersey; Phoenix, Arizona; Zurich, Switzerland; and Belfast, Northern Ireland, as well as operations in Richmond, Virginia and Quebec, Canada.

29 Mar 2010

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Sinovac Biotech Ltd., a leading China-based vaccine manufacturer, announced today it has entered into exclusive license, supply and distribution agreements with Parenteral Biotech Ltd., a subsidiary of Parenteral Drugs (India), Ltd., an India-based pharmaceutical company. Pursuant to the agreements, Parenteral is authorized to register, supply and distribute Sinovac's Anflu (seasonal influenza vaccine) and PANFLU.1 (H1N1 vaccine) to the government of India and private market in India. Currently, the registration process is ongoing in India.

29 Mar 2010

Redpoint Bio announces revenue of $1.9M for full-year 2009

Redpoint Bio Corporation, a company focused on the development of healthier foods and beverages and new approaches to the treatment of diabetes and obesity, today announced financial and operational results for the quarter and year ended December 31, 2009.

29 Mar 2010

BIO praises Reps. for introducing bill to extend Cellulosic Ethanol Production Tax Credit

Consistent, sustained and diverse federal support is the key to rapid growth of a sustainable advanced biofuel industry. The Biotechnology Industry Organization today thanked Reps. Earl Pomeroy (D-N.D.) and John Shimkus (R-Ill.) for introducing a bill to extend by three years the Cellulosic Ethanol Production Tax Credit. BIO also called for extending tax code parity to algae-based biofuels and a full range of innovative biobased technologies.

29 Mar 2010

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Sigma® Life Science, the innovative biological products and services brand of Sigma-Aldrich®, today announced that it has added 2,200 new Prestige Antibodies® powered by Atlas Antibodies to its industry-leading portfolio.

From Atlas Antibodies AB 29 Mar 2010

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

In an article published in Nature Genetics today, scientists at the ALS Therapy Development Institute describe how they have linked an unbiased gene expression profiling effort to the identification and successful preclinical testing of a potential novel therapeutic for amyotrophic lateral sclerosis.

29 Mar 2010

SMARTube technology helps physicians create index to get accurate picture of HIV infection

New data presented at the Center for Disease Control -sponsored 2010 HIV Diagnostics Conference suggests that an assay based on SMARTube™ technology may prove useful in developing a standardized measure for estimating what proportion of those infected with HIV have become recently infected.

29 Mar 2010

DSA to discuss challenges in drug development at Late Phase Drug Development World 2010

Drug Safety Alliance, a global leader in drug safety and pharmacovigilance, announced that Dr. Elizabeth Garrard, PharmD, RPh, would participate in “Late Phase Drug Development World 2010,” a first of its kind strategic forum addressing challenges in drug development.

27 Mar 2010

Maryland Technology Enterprise Institute director receives President's Award

Martha Connolly, director of the Maryland Technology Enterprise Institute Maryland Industrial Partnerships program at the University of Maryland, was given the President's Award at the Greater Baltimore Committee's fifth annual Bioscience Awards ceremony, university officials announce today.

27 Mar 2010

Ontario announces increase in budget for research and innovation, OBIO applauds

Urgently needed capital should become more accessible to Ontario’s bioscience companies and help create jobs in the biotechnology sector, thanks to Ontario’s 2010 budget. An announced increase in the budget of the Ministry of Research and Innovation coupled with anticipated adjustments to existing funding programs designed to encourage research and innovation are applauded by Ontario Bioscience Industry Organization (OBIO).

27 Mar 2010

ETSU wins $9.1M federal stimulus grant from NIH

East Tennessee State University has won a $9.1 million federal stimulus grant from the National Institutes of Health. It is the largest federal grant ever awarded to the university's James H. Quillen College of Medicine.

27 Mar 2010

Innovative biotechnology leading to better understanding of complex diseases

As recently stated in the Glenville Democrat, innovative biotechnology is leading to a greater understanding of complex diseases and better tools for diagnosing and treating conditions such as heart disease, cancer and diabetes.

27 Mar 2010

Market update on CBI's planned acquisition of Shanghai-based GL-Biochem

Commonwealth Biotechnologies, Inc. is pleased to provide this market update about its planned acquisition of Shanghai-based GL-Biochem and its associated businesses, one of the largest global suppliers of research-grade peptide products and peptide reagents.

27 Mar 2010

Neurologix reports net loss of $13.5M for year ended December 31, 2009

Neurologix, Inc., a biotechnology company engaged in the development of innovative therapies for the brain and central nervous system, today announced its financial results for the year ended December 31, 2009.

26 Mar 2010

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Invida Group, the leading provider of healthcare brands and services to the Asia Pacific region, today announced that its contract with Swiss biotechnology company, Actelion, has been extended through 2015 to continue commercialization of Tracleer® for the treatment of pulmonary arterial hypertension (PAH) in crucial markets throughout Asia. Actelion signed with Invida initially in 2005, and has extended the contract to market the company’s lead product, Tracleer, in Thailand, Malaysia, Philippines, Vietnam, and Hong Kong

26 Mar 2010

Biotechnology News and Research

Generex Biotechnology announces FDA Expanded Access Treatment IND Program for Generex Oral-lyn

Neogen's third-quarter fiscal 2010 revenues up 21%

Chakra Biotech completes MYR18.2m Series B investment round

Final results from Novavax' Phase II clinical trial of trivalent seasonal influenza VLP vaccine announced

Ligand Pharmaceuticals' LGD-4033 SARM Phase I study data featured at 14th endocrinology congress

Celerion completes acquisition of MDS Pharma Services' early stage clinical development operations

Parenteral Biotech to supply and distribute Sinovac Biotech's Anflu and PANFLU.1 vaccines in India

Redpoint Bio announces revenue of $1.9M for full-year 2009

BIO praises Reps. for introducing bill to extend Cellulosic Ethanol Production Tax Credit

New Prestige Antibodies powered by Atlas Antibodies added to Sigma Life Science's portfolio

Scientists link gene expression profiling effort to identify potential novel therapeutic for ALS

SMARTube technology helps physicians create index to get accurate picture of HIV infection

DSA to discuss challenges in drug development at Late Phase Drug Development World 2010

Maryland Technology Enterprise Institute director receives President's Award

Ontario announces increase in budget for research and innovation, OBIO applauds

ETSU wins $9.1M federal stimulus grant from NIH

Innovative biotechnology leading to better understanding of complex diseases

Market update on CBI's planned acquisition of Shanghai-based GL-Biochem

Neurologix reports net loss of $13.5M for year ended December 31, 2009

Invida to continue commercialization of Actelion's Tracleer for PAH in crucial Asian markets

Industry Focus eBook - Biotechnology (4th edition) eBook

Designing fluidic architecture for scalable diagnostic platforms

Evaluating new approaches for rare disease genomics

Expanding access to NMR with the Fourier 80 Duo

Latest News